// App-Quantinova.ai

3739 : Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib

Researchers

Presenter

  • Daniel J Goff

Principal Investigators

  • Janine Low-Marchelli

  • Mark D. Minden

  • Giovanni Martinelli

  • Marco A. Marra

  • Kelly A Frazer

  • Maurizio Pellecchia

  • John C. Reed

  • Catriona Jamieson

  • Angela C Court Recart

  • Kristen M. Smith

  • Wenxue Ma

  • Anil Sadarangani

  • Alice Y. Shih

  • Jun Wei

  • Dayong Zhai

  • Jason Gotlib

Medical Centers

  • Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy

Locations

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

  • Breakpoint Cluster Region

Drug/Treatment

  • sabutoclax

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved